Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04561089 · ClinicalTrials.gov registry record
Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel
A clinical trial, sponsored by Illumina.
- Completed
- Registry status
- 763
- Enrollment target
NCT04561089 is a clinical trial that has completed, run by Illumina. The registered enrollment target is 763 participants.
The verdict
NCT04561089 has completed, sponsored by Illumina.
- COMPLETED
- Registry status
- 763 participants
- Enrollment target
Study Summary
"This is a prospective, multi-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one nasal swab will be tested with an EUA approved COVID test. The other nasal swab sample will be stored and a subset (approximately 250 specimens) will be tested with the COVIDSeq Test. Results of all testing will be provided to the sponsor for statistical analysis. Positive results from COVIDSeq Test using saliva and/or the comparator EUA test will be provided to subjects so participants can be referred for further evaluation (outside the study). No medical treatment, guidance on treatment decisions, nor medical care will be provided. "
Interventions
- DIAGNOSTIC_TEST COVIDSeq Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 763 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2021-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04561089
The ClinicalTrials.gov registry entry for NCT04561089 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 763 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Illumina, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which COVIDSeq Test is the first listed.
NCT04561089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04561089 about?
NCT04561089 is a clinical study titled "Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel". "This is a prospective, multi-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one n...
What is the current status of trial NCT04561089?
This trial is currently completed. The enrollment target is 763 participants. The study started on 2020-02-13. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT04561089?
The interventions under investigation include: COVIDSeq Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04561089?
This trial is sponsored by Illumina, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.